
Alector Inc (ALEC) Stock Forecast & Price Target
Alector Inc (ALEC) Analyst Ratings
Bulls say
Alector Inc is advancing its clinical-stage pipeline, showing promising results in neurodegeneration therapies, particularly with AL001, which demonstrated a substantial 48% reduction in clinical progression over 12 months compared to controls. The extended double-blinded treatment period of 96 weeks in the Phase 3 trial is expected to yield even greater improvements in the CDR plus NACC FTLD-SB scores, indicating the potential for enhanced therapeutic efficacy. Furthermore, Alector's innovative approach that targets a novel domain on the transferrin receptor may provide significant advantages in both central nervous system penetration and systemic uptake, reinforcing the positive outlook for the company's future performance.
Bears say
Alector Inc. is experiencing significant challenges inherent to the biopharmaceutical industry, including the risk of unexpected outcomes from clinical trials and regulatory uncertainty. Additionally, the company faces increased pressure from complex and price-sensitive market conditions, which may impact its ability to successfully commercialize its product candidates. Furthermore, specific risks such as potential negative readouts or delays in clinical trials and off-target toxicity in its therapies contribute to a negative outlook on its stock.
This aggregate rating is based on analysts' research of Alector Inc and is not a guaranteed prediction by Public.com or investment advice.
Alector Inc (ALEC) Analyst Forecast & Price Prediction
Start investing in Alector Inc (ALEC)
Order type
Buy in
Order amount
Est. shares
0 shares